Why the study?
Atrial fibrillation is the most frequent cardiac arrhythmia and causes heart failure and stroke, but the role of adaptive immunity driven by typical risk factors remains unclear.
Does genetic or anti-CD20 antibody-mediated B cell and plasma cell depletion reduce atrial fibrillation inducibility, burden, and electrical remodeling in a mouse model of hypertension, obesity, and mitral valve regurgitation (HOMER)?
Does genetic or anti-CD20 antibody-mediated B cell and plasma cell depletion reduce atrial fibrillation inducibility, burden, and electrical remodeling in a mouse model of hypertension, obesity, and mitral valve regurgitation (HOMER)?
Answers are grounded in this paper and cite their sources.
This preclinical study demonstrates that atrial fibrillation risk factors trigger an adaptive immune response where B cell-derived anti-ADRB1 autoantibodies disrupt cardiomyocyte calcium handling and promote arrhythmia, identifying humoral immunity and B cell depletion as potential therapeutic targets for AF.
Atrial fibrillation, the most frequent cardiac arrhythmia, causes heart failure and stroke. Here we describe that combining the typical risk factors of atrial fibrillation (hypertension, obesity and mitral valve regurgitation (HOMER)) activates adaptive immunity in wild-type mice, ultimately causing electrical remodeling of cardiomyocytes. In HOMER mice, dendritic cells expanded in the left atria and heart-draining lymph nodes, where we detected cardiomyocyte-derived proteins. Systemically expanding B cells, while exposed to interferon-α, produced autoantibodies that disrupted calcium handling in cardiomyocytes. Depleting B cells by using μMT HOMER mice or plasma cells by using Mb1cre/+ Prdm1fl/fl HOMER mice reduced atrial fibrillation while mitigating the prolonged action potential duration we observed in the left atria of HOMER mice. CD20 antibody B cell depletion, a clinical tool in treating lymphoma and autoimmune disease, reduced atrial fibrillation fivefold in HOMER mice. Targeting humoral immunity may provide therapeutic avenues for patients with autoantibody-induced atrial fibrillation. Yamazoe et al. show that B cell-derived autoantibodies contribute to the development of atrial fibrillation, suggesting that targeting the humoral immune response may represent a viable therapeutic approach.
No takes yet. Share an insight, caveat, or question.
Yamazoe et al. (2025) studied Atrial fibrillation. Anti-CD20 monoclonal antibody vs. Isotype control antibody was evaluated on Atrial fibrillation inducibility (fivefold reduction, p=0.029).
Synapse has enriched 10 related papers. Consider them for comparative context: